Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Though low, this figure is three times the rate of discontinuation seen in clinical trials.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
All women who completed follow-up in a small trial were cured, and none of their infants contracted the virus.
Even those who did not qualify for a treatment shorter than 12 weeks did well on the regimen in a real-world study.
Real-world results of eight weeks of the hepatitis C virus treatment Harvoni (ledipasvir/sofosbuvir) are excellent.
Two new treatments have hit the market, offering more options for those with genotypes 3 and 4.
In a recent letter, the politician notes that the VA has stopped enrolling HCV-positive veterans because of budget constraints.
This marks a 15-fold increase for liver disease drugs since new HCV therapies started rolling out in 2013.
In most cases, Harvoni is cost effective when compared with older hepatitis C treatments, but treating all of those in need will be highly exp...
Analysts credit the spark in innovation to the FDA’s new ’Breakthrough Therapy Designation.’
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.